Baxdrostat + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uncontrolled Hypertension
Conditions
Uncontrolled Hypertension
Trial Timeline
Jun 10, 2024 → Dec 4, 2024
NCT ID
NCT06336356About Baxdrostat + Placebo
Baxdrostat + Placebo is a phase 2 stage product being developed by AstraZeneca for Uncontrolled Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT06336356. Target conditions include Uncontrolled Hypertension.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07007793 | Phase 3 | Recruiting |
| NCT06336356 | Phase 2 | Completed |
| NCT06344104 | Phase 3 | Active |
| NCT06168409 | Phase 3 | Completed |
| NCT06034743 | Phase 3 | Completed |
Competing Products
17 competing products in Uncontrolled Hypertension
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KHK4563 + KHK4563 + KHK4563 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| HR17031 injection + insulin glargine | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Baxdrostat + Placebo | AstraZeneca | Phase 3 | 77 |
| Tralokinumab | AstraZeneca | Phase 3 | 77 |
| Baxdrostat + Placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Experimental: Tralokinumab | AstraZeneca | Phase 3 | 77 |
| Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E | AstraZeneca | Phase 1 | 33 |
| CIN-107 + Placebo | AstraZeneca | Phase 2 | 52 |
| Pegloticase + Methotrexate (MTX) | Amgen | Approved | 84 |
| Pegloticase | Amgen | Approved | 84 |
| Pegloticase + Methotrexate | Amgen | Phase 3 | 76 |
| Pegloticase + Methotrexate (MTX) | Amgen | Approved | 84 |
| Pegloticase with MTX | Amgen | Approved | 84 |
| abrocitinib | Pfizer | Pre-clinical | 22 |
| REGN5381 + Placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |
| SAL0140 + SAL0140 placebo | Shenzhen Salubris Pharmaceuticals | Phase 1 | 32 |